Table 1.

Patient characteristics for all patients and according to type of insurance

All, N = 3,142Public, N = 2,155 (69%)Private, N = 987 (31%)
n (%)n (%)n (%)Pa
Ethnicity<0.001
 Caucasian1,450 (60)986 (55)464 (75)
 African descendent84 (4)61 (3)23 (4)
 Asian7 (0)5 (0)2 (0)
 Mixed (parda)885 (37)753 (42)132 (21)
 Unknown716 (23)350 (16)366 (37)<0.001
Menopause status0.614
 Postmenopausal1,685 (62)1,242 (63)443 (61)
 Premenopausal1,023 (38)745 (38)278 (39)
 Unknown434 (14)168 (8)266 (27)<0.001
Cancer type<0.001
 Invasive ductal1,899 (83)1,459 (86)440 (77)
 Invasive lobular139 (6)87 (5)52 (9)
 Other invasive74 (3)57 (3)17 (3)
 DCIS161 (7)100 (6)61 (11)
 LCIS4 (0)2 (0)2 (0)
Clinical stage at diagnosis<0.001
 0–I504 (20)261 (15)243 (33)
 IIA722 (29)509 (29)213 (29)
 IIB466 (19)331 (19)135 (18)
 III702 (28)588 (33)114 (16)
 IV131 (5)100 (6)31 (4)
 Unknown617 (20)366 (17)251 (25)<0.001
Grade<0.001
 G1138 (10)97 (10)41 (11)
 G2760 (57)558 (58)202 (53)
 G3379 (28)279 (29)100 (26)
 GX65 (5)29 (3)36 (10)
 Unknown1,800 (57)1,192 (55)608 (62)<0.001
Hormone receptor (ER and/or PR)0.751
 Positive1,945 (62)1,330 (62)615 (62)
 Negative1,197 (38)825 (38)372 (38)
 HER2b1,797 (57)1,159 (54)638 (65)
 Positivec224 (13)117 (10)107 (17)0.905
 Negativec839 (47)442 (38)397 (62)
 Unknown/not performedc734 (41)600 (52)134 (21)<0.001

Abbreviations: DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor.

  • aP values in each category are calculated for comparisons between known variables within each group and separately for the unknown from each group.

  • bOnly patients included from 2006 are shown here, because HER2 testing was not routine in 2001.

  • cPercentages were calculated as the number of patients in each cell related to the total number of patients available for HER2 testing in each group. Percentages do not sum 1 due to rounding.